Sangui Biotech International Inc (SGBI) financial statements (2022 and earlier)

Company profile

Business Address 352 SOUTH 200 WEST
FARMINGTON, UT 84025
State of Incorp. CO
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q2
9/30/2021
Q1
6/30/2021
Q4
3/31/2021
Q3
12/31/2020
Q2
9/30/2020
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8133012921
Cash and cash equivalents8133012921
Receivables312423271534
Prepaid expense16912151410
Other undisclosed current assets 32121
Total current assets:564967554166
Noncurrent Assets
Property, plant and equipment111122
Other undisclosed noncurrent assets788566707981
Total noncurrent assets:798667728183
TOTAL ASSETS:135135134126121149
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Debt767746753746740679
Due to related parties696662575548
Other liabilities1     
Other undisclosed current liabilities147157140149146164
Total current liabilities:984968955952940892
Noncurrent Liabilities
Long-term debt and lease obligation535855576363
Operating lease, liability535855576363
Other undisclosed noncurrent liabilities(53)(58)(55)(57)(63)(63)
Total noncurrent liabilities:5358 576363
Total liabilities:1,0371,0271,0091,0101,003955
Stockholders' equity
Stockholders' equity attributable to parent(250)(239)(224)(233)(233)(158)
Common stock33,10033,10033,08833,02833,02833,028
Treasury stock, value(19)(19)(19)(19)(19)(19)
Additional paid in capital4,5134,5134,5134,5134,5134,513
Accumulated other comprehensive income898990909191
Accumulated deficit(37,932)(37,922)(37,895)(37,845)(37,845)(37,771)
Stockholders' equity attributable to noncontrolling interest(653)(653)(652)(650)(649)(648)
Total stockholders' equity:(902)(892)(875)(883)(882)(806)
TOTAL LIABILITIES AND EQUITY:135135134126121149

Income statement (P&L) ($ in thousands)

12/31/2021
Q2
9/30/2021
Q1
6/30/2021
Q4
3/31/2021
Q3
12/31/2020
Q2
9/30/2020
Q1
Revenues221914211120
Gross profit:221914211120
Operating expenses(42)(62)(54)(50)(49)(64)
Operating loss:(20)(44)(40)(28)(38)(44)
Nonoperating income (expense)1016(12)28(37)(32)
Foreign currency transaction gain (loss), before tax1420(7)32(32)(27)
Interest and debt expense(9)(5)(5)(5)(4)(4)
Loss before gain (loss) on sale of properties:(20)(33)(56)(5)(80)(80)
Other undisclosed net income955544
Net loss:(10)(28)(52)(1)(75)(76)
Other undisclosed net income attributable to parent012111
Net loss available to common stockholders, diluted:(10)(27)(50)(0)(74)(75)

Comprehensive Income ($ in thousands)

12/31/2021
Q2
9/30/2021
Q1
6/30/2021
Q4
3/31/2021
Q3
12/31/2020
Q2
9/30/2020
Q1
Net loss:(10)(28)(52)(1)(75)(76)
Other comprehensive income11285317676
Comprehensive income, net of tax, attributable to parent:001010

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: